Login Register Cart 0
Generic placeholder image

Anti-Infective Agents

Editor-in-Chief

ISSN (Print): 2211-3525
ISSN (Online): 2211-3533

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Synthesis of Quinine-Triazole Derivatives (QNTDs) with Antifungal Potency

Author(s): Adarsh Sahu* and Ramkishore Agrawal

Volume 20, Issue 3, 2022

Published on: 11 April, 2022

Article ID: e240122200465 Pages: 5

DOI: 10.2174/2211352520666220124101052

Price: $65

Abstract

Background: Reduced efficacy of the available antifungal drugs is the major public health concern of the population all over the world. Despite significant advances in the treatment of these life-threatening infections, severe toxicity and increasing median effective dose have limited the efficacy of frontline therapy applicable against them.

Objective: The quintessential occurrence of systemic toxicity handicaps the clinical utility of currently available antifungal drugs. 1,2,3-Triazoles in the same context are relatively less toxic. Consequently, conjugation of quinine with the triazole moiety for enhanced efficacy and reduced toxicity have been excessively envisaged and reported in the context of a range of activities ranging from inflammation to cancer, however lack of toxicity profile sabotages the translation of the laboratory prototype into successful clinical practice.

Methods: We herein report the synthesis and characterization of a series of quinine triazole hybrids via o-mesylation followed by azide displacement, then reacting it with aliphatic and aromatic alkynes in water: t-butanol mixture. The reaction was carried in the presence of copper sulphate and sodium ascorbate. Product 6a-s was screened for in-vitro antifungal activity. The in-vitro antifungal potential of synthesized compounds was estimated against prominent fungal strains (Candida albicans, Aspergillus niger and, Aspergillus clavatus).

Results: The results showed that some of the synthesized compounds exhibited marked activity. Compounds 6a, 6b, 6c, 6d, 6g, and 6q showed significant antifungal activity at micromolar concentration. The studies revealed that some of the compounds exhibited activities more than that of reference drugs. The compound containing thiazole ring 6c is the most potent compound of the series.

Conclusion: Compound 6c was found to be the most vigorous against C. albicans, A. niger, A. clavatus with MIC values of 119.4, 112.7, and 121.3 μM/mL, respectively. Our SAR study revealed that the introduction of the 1,2,3-triazole ring in the structure of quinine modulated its potency for treating fungal infection.

Keywords: Quinine, triazole, antifungal, candida albicans, aspergillus niger, aspergillus clavatus.

[1]
Wiederhold, N.P. Antifungal resistance: Current trends and future strategies to combat. Infect. Drug Resist., 2017, 10, 249-259.
[http://dx.doi.org/10.2147/IDR.S124918] [PMID: 28919789]
[2]
Perlin, D.S.; Rautemaa-Richardson, R.; Alastruey-Izquierdo, A. The global problem of antifungal resistance: Prevalence, mechanisms, and management. Lancet Infect. Dis., 2017, 17(12), e383-e392.
[http://dx.doi.org/10.1016/S1473-3099(17)30316-X ] [PMID: 28774698]
[3]
Fisher, M.C.; Hawkins, N.J.; Sanglard, D.; Gurr, S.J. World-wide emergence of resistance to antifungal drugs challenges human health and food security. Science, 2018, 360(6390), 739-742.
[http://dx.doi.org/10.1126/science.aap7999] [PMID: 29773744]
[4]
Kean, R.; Ramage, G. Combined antifungal resistance and biofilm tolerance: The global threat of Candida auris. MSphere, 2019, 4(4), e00458-e19.
[http://dx.doi.org/10.1128/mSphere.00458-19] [PMID: 31366705]
[5]
Gupta, A.K.; Tomas, E. New antifungal agents. Dermatol. Clin., 2003, 21(3), 565-576.
[http://dx.doi.org/10.1016/S0733-8635(03)00024-X ] [PMID: 12956208]
[6]
Musiol, R.; Serda, M.; Hensel-Bielowka, S.; Polanski, J. Quinoline-based antifungals. Curr. Med. Chem., 2010, 17(18), 1960-1973.
[http://dx.doi.org/10.2174/092986710791163966] [PMID: 20377510]
[7]
Irfan, M.; Alam, S.; Manzoor, N.; Abid, M. Effect of quinoline based 1,2,3-triazole and its structural analogues on growth and virulence attributes of Candida albicans. PLoS One, 2017, 12(4)e0175710
[http://dx.doi.org/10.1371/journal.pone.0175710] [PMID: 28430797]
[8]
Kacprzak, K.; Skiera, I.; Piasecka, M.; Paryzek, Z. Alkaloids and isoprenoids modification by copper (I)-catalyzed Huisgen 1, 3-dipolar cycloaddition (click chemistry): Toward new functions and molecular architectures. Chem. Rev., 2016, 116(10), 5689-5743.
[http://dx.doi.org/10.1021/acs.chemrev.5b00302] [PMID: 27115045]
[9]
Faidallah, H.M.; Panda, S.S.; Serrano, J.C.; Girgis, A.S.; Khan, K.A.; Alamry, K.A.; Therathanakorn, T.; Meyers, M.J.; Sverdrup, F.M.; Eickhoff, C.S.; Getchell, S.G.; Katritzky, A.R. Synthesis, antimalarial properties and 2D-QSAR studies of novel triazole-quinine conjugates. Bioorg. Med. Chem., 2016, 24(16), 3527-3539.
[http://dx.doi.org/10.1016/j.bmc.2016.05.060] [PMID: 27298002]
[10]
Jones, R.A.; Panda, S.S.; Hall, C.D. Quinine conjugates and quinine analogues as potential antimalarial agents. Eur. J. Med. Chem., 2015, 97, 335-355.
[http://dx.doi.org/10.1016/j.ejmech.2015.02.002] [PMID: 25683799]
[11]
Wells, T.N.; Hooft van Huijsduijnen, R.; Van Voorhis, W.C. Malaria medicines: A glass half full? Nat. Rev. Drug Discov., 2015, 14(6), 424-442.
[http://dx.doi.org/10.1038/nrd4573] [PMID: 26000721]
[12]
Peyton, L.R.; Gallagher, S.; Hashemzadeh, M. Triazole anti-fungals: A review. Drugs Today (Barc), 2015, 51(12), 705-718.
[PMID: 26798851]
[13]
Worth, L.J.; Blyth, C.C.; Booth, D.L.; Kong, D.C.M.; Marriott, D.; Cassumbhoy, M.; Ray, J.; Slavin, M.A.; Wilkes, J.R. Opti-mizing antifungal drug dosing and monitoring to avoid toxici-ty and improve outcomes in patients with haematological dis-orders. Intern. Med. J., 2008, 38(6b), 521-537.
[http://dx.doi.org/10.1111/j.1445-5994.2008.01726.x ] [PMID: 18588523]
[14]
Williams, A.D. Foye’s Principles of Medicinal Chemistry, 5th ed; Wolters Kluwer: The Netherlands, 2017.
[15]
Brunton, L.L. Goodman and Gilman’s manual of pharmacol-ogy and therapeutics; McGraw-Hill: New York, 2014.
[16]
Sahu, A.; Das, D.; Agrawal, R.K.; Gajbhiye, A. Bio-isosteric replacement of amide group with 1,2,3-triazole in phenacetin improves the toxicology and efficacy of phenacetin-triazole conjugates (PhTCs). Life Sci., 2019, 228, 176-188.
[http://dx.doi.org/10.1016/j.lfs.2019.05.004] [PMID: 31059688]
[17]
Liles, N.W.; Page, E.E.; Liles, A.L.; Vesely, S.K.; Raskob, G.E.; George, J.N. Diversity and severity of adverse reactions to quinine: A systematic review. Am. J. Hematol., 2016, 91(5), 461-466.
[http://dx.doi.org/10.1002/ajh.24314] [PMID: 26822544]
[18]
Sahu, A.; Agrawal, R.K.; Pandey, R. Synthesis and systemic toxicity assessment of quinine-triazole scaffold with antiproto-zoal potency. Bioorg. Chem., 2019, 88102939
[http://dx.doi.org/10.1016/j.bioorg.2019.102939] [PMID: 31028993]
[19]
Sahu, A.; Sahu, P.; Agrawal, R. Synthesis, pharmacological and toxicological screening of penicillin-triazole conjugates (PNTCs). ACS Omega, 2019, 4(17), 17230-17235.
[http://dx.doi.org/10.1021/acsomega.9b01724] [PMID: 31656896]
[20]
Peters, W.; Richards, W.H.G. Eds.;. Handbook of Experimental Pharmacology; Springer-Verlag: Germany, 1984; pp. 179-200.
[21]
Morita, J.I.; Nakatsuji, H.; Misaki, T.; Tanabe, Y. Water-solvent method for tosylation and mesylation of primary alcohols promoted by KOH and catalytic amines. Green Chem., 2005, 7(10), 711-715.
[http://dx.doi.org/10.1039/b505345e]
[22]
Scriven, E.F.; Turnbull, K. Azides: Their preparation and syntheticuses. Chem Rev, 1988, 88(2), 297-368.
[http://dx.doi.org/10.1021/cr00084a001]

Rights & Permissions Print Cite
Article Metrics
39
1
© 2024 Bentham Science Publishers | Privacy Policy